

Pharmacological treatment options for *mast cell activation disease*

Gerhard J. Molderings¹ · Britta Haenisch² · Stefan Brettner³ · Jürgen Homann⁴ · Markus Menzen⁴ · Franz Ludwig Dumoulin⁴ · Jens Panse⁵ · Joseph Butterfield⁶ · Lawrence B. Afrin⁷

Received: 24 March 2016 / Accepted: 11 April 2016 / Published online: 30 April 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract *Mast cell activation disease* (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. In most cases, treatment of MCAD is directed primarily at controlling the symptoms associated with MC mediator release. In advanced forms, such as aggressive SM and MCL, agents targeting MC

proliferation such as kinase inhibitors may be provided. Targeted therapies aimed at blocking mutant protein variants and/or downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies. Since clinicians are often underprepared to evaluate, diagnose, and effectively treat this clinically heterogeneous disease, we seek to familiarize clinicians with MCAD and review current and future treatment approaches.

Keywords Mast cell · Mast cell activation disease · Systemic mastocytosis · Systemic mast cell activation syndrome · Therapy

✉ Gerhard J. Molderings
molderings@uni-bonn.de

¹ Institute of Human Genetics, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany

² German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

³ Department of Oncology, Hematology and Palliative Care, Kreiskrankenhaus Waldbröl, Waldbröl, Germany

⁴ Allgemeine Innere Medizin, Gastroenterologie und Diabetologie, Gemeinschaftskrankenhaus, Bonn, Germany

⁵ Department of Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany


⁶ Program for the Study of Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, MN 55905, USA

⁷ Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA

Introduction

Mast cells (MCs, Fig. 1) are immune cells of hematopoietic origin found in all human tissues, especially at the environmental interfaces. They act as both effector and regulatory cells and play a central role in adaptive and innate immunity (Anand et al. 2012; Gri et al. 2012). Their important role in immunological as well as non-immunological processes is reflected by the large number of mediators (>200) including pre-stored ones such as histamine and tryptase as well as numerous mediators synthesized de novo in response to allergic or non-immune triggers such as chemokines and cytokines, by which MCs may influence other cells (Lundequist and Pejler 2011; Ibelgaufts 2016). Their evolved arrays of sensory and response mechanisms engender diverse havoc when MC dysfunction emerges.

The umbrella term *mast cell activation disease* (MCAD; Akin et al. 2010) comprises the full spectrum of primary systemic MC disease, i.e., *systemic mastocytosis* (SM) which is



Resting mast cell

Activated mast cell

Fig. 1 May-Grünwald/Giemsa stain of a resting human mast cell and a mast cell following activation-induced degranulation. Note the loss of granule staining. Mast cells obtained from the human bone marrow, magnification 1000×

further divided into several subtypes (Valent et al. 2007; Tables 1 and 2), primary *MC activation syndrome* (MCAS; Table 3; Molderings et al. 2011a; Hamilton et al. 2011; Valent et al. 2012), and *MC leukemia* (MCL). Pathogenetically, MCAD denotes a group of polygenic MC disorders (Molderings 2015, 2016) characterized by aberrant release of variable subsets of MC mediators and also an accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (SM and MCL) or morphologically ordinary MCs due to decreased apoptosis (MCAS; Kohno et al. 2005; Aichberger et al. 2009; Karlberg et al. 2010a). According to recent molecular genetic findings (Molderings 2015, 2016; Haenisch et al. 2014; Lasho et al. 2016), the subclasses and clinical subtypes of MCAD do not represent distinct disease entities but should be more accurately regarded as variable presentations of a common generic state of MC dysfunction (Molderings et al. 2007, 2010; Hermine et al. 2008; Akin et al. 2010). Due to both the widespread distribution of MCs and the great heterogeneity of aberrant mediator expression patterns, symptoms can occur in virtually all organs and tissues; hence, the clinical presentation of MCAD is very diverse, sometimes to the even-

Table 1 WHO 2008 diagnostic criteria for systemic mastocytosis (Valent et al. 2001)

Major criterion:

1. Multifocal, dense aggregates of MCs (15 or more) in sections of the bone marrow or other extracutaneous tissues and confirmed by tryptase immunohistochemistry or other special stains

Minor criteria:

1. Atypical or spindled appearance of at least 25 % of the MCs in the diagnostic biopsy
2. Expression of CD2 and/or CD25 by MCs in the marrow, blood, or extracutaneous organs
3. KIT codon 816 mutation in the marrow, blood, or extracutaneous organs
4. Persistent elevation of serum total tryptase >20 ng/ml

Diagnosis of SM made by either (1) the major criterion plus any one of the minor criteria or (2) any three minor criteria

further-confounding point of presenting opposite abnormalities in different patients (or even in the same patient at different times, or in different sites in the same patient at the same time). While the prevalence of SM in Europeans ranges between 0.3 and 13 per 100,000 (Haenisch et al. 2012; Cohen et al. 2014; van Doormaal et al. 2013), the prevalence of MCAS may be as high as 17 % (in Germany; Molderings et al. 2013a, b).

This review focuses on the current state of drug therapy in SM and MCAS and describes perspectives of promising new approaches for drug treatment. Compounds in various stages of preclinical and clinical development are summarized in tables. We first describe drugs that are currently available and either are used on a regular basis in MCAD therapy or have been used successfully in single MCAD cases. In this context, it should be noted that there is no official guideline for treatment of MCAD.

Treatment options

Due to its genetic roots, MCAD generally is regarded as incurable. Recent mutational studies revealed that each patient has an individual pattern of genetic and epigenetic alterations which may affect the intracellular signal transduction pathways and receptive sites involved in sensory perception. As a consequence, mediator formation and release as well as inhibition of apoptosis and/or increase in proliferation are determined by individual genetic and epigenetic conditions (Fig. 2) and represent potential targets for therapy. Hence, there is need of highly personalized therapy for the disease. Unfortunately (with regard to easy detection), most genetic alterations (with a few exceptions such as certain mutations

Table 2 Classification of systemic mastocytosis (modified form Valent et al. 2007)

| Categories of systemic mastocytosis (SM) | Subtypes |
|---|--|
| Indolent systemic mastocytosis | <ul style="list-style-type: none"> • Smoldering systemic mastocytosis • Isolated bone marrow mastocytosis • Well-differentiated systemic mastocytosis |
| Aggressive systemic mastocytosis (ASM) | <ul style="list-style-type: none"> • ASM in transformation |
| Systemic mastocytosis with an associated clonal hematological non-mast cell lineage disease | <ul style="list-style-type: none"> • SM-acute myeloid leukemia • SM-myelodysplastic syndrome • SM-myeloproliferative neoplasm • SM-chronic myelomonocytic leukemia • SM-chronic eosinophilic leukemia • SM-non-Hodgkin lymphoma • SM-multiple myeloma |

Table 3 Current provisional criteria to define *mast cell activation syndrome* (MCAS; modified from Afrin and Molderings 2014)**Major criterion**

Constellation of clinical complaints attributable to pathologically increased mast cell activity (mast cell mediator release syndrome)

Minor criteria

1. Focal or disseminated increased number of mast cells in marrow and/or extracutaneous organ(s) (e.g., gastrointestinal tract biopsies; CD117-, tryptase-, and CD25-stained)
2. Abnormal spindle-shaped morphology in >25 % of mast cells in marrow or other extracutaneous organ(s)
3. Abnormal mast cell expression of CD2 and/or CD25 (i.e., co-expression of CD117/CD25 or CD117/CD2)
4. Detection of genetic changes in mast cells from the blood, bone marrow, or extracutaneous organs for which an impact on the state of activity of affected mast cells in terms of an increased activity has been proven
5. Evidence (typically from body fluids such as whole blood, serum, plasma, or urine) of above-normal levels of mast cell mediators including:
 - Tryptase in the blood
 - Histamine or its metabolites (e.g., *N*-methylhistamine) in the urine
 - Heparin in the blood
 - Chromogranin A in the blood (potential confounders of cardiac or renal failure, neuroendocrine tumors, or recent proton pump inhibitor use were excluded)
 - Other relatively mast cell-specific mediators (e.g., eicosanoids including prostaglandin PGD₂, its metabolite 11-β-PGF_{2α}, or leukotriene E₄)
6. Symptomatic response to inhibitors of mast cell activation or mast cell mediator production or action (e.g., histamine H₁ and/or H₂ receptor antagonists, cromolyn)

Diagnosis of MCAS made by either (1) the major criterion plus any one of the minor criteria or (2) any three minor criteria

in tyrosine kinase KIT, e.g., KIT^{D816V}) do not alter the morphology and immunohistochemistry of the surface of the affected MCs. Thus, in most cases except for patients with the reliably identifiable D816V mutation, it cannot be decided by simple tests whether MCs found in biopsies are genetically altered MCs or physiological MCs.

First-line treatment options

Step 1 in managing most situations of inappropriate MC activation is identifying the individual patient's unique triggers (chemical, physical, or otherwise) as precisely as possible and then desensitizing when possible (in truth, rarely) and otherwise practicing avoidance. With respect to drug treatment, only a few clinical therapeutic trials have been

conducted in SM (midostaurin, cladribine, masitinib; Table 4), and there have been no therapeutic trials in MCAS yet. Most information about therapeutic effectiveness in MCAD has been found in small case series (Table 4) and single case reports, perhaps unsurprising given the mutational heterogeneity of the disease and thus the heterogeneity of its patterns of clinical presentation and therapeutic responsiveness. Therefore, in the future, it may be helpful to establish an international patient registry in partnership with existing registries so that issues related to molecular and clinical MCAD phenotypes can be adequately addressed. As the primary feature of MCAD is inappropriate MC activation (Molderings et al. 2011a, b; Pardani 2013; Cardet et al. 2013), mainstays of first-line management are identification and avoidance of triggers plus therapies to control MC mediator production (both primary as well as secondary/reactive; Table 5) as well as their action (Table 6).




Fig. 2 Scheme of conditions responsible in MCAD for the development of individual phenotypes

Subordinate therapeutic options

Continuous diphenhydramine infusion

Occasional patients suffer nearly continuous anaphylactoid and/or dysautonomic states poorly controlled by intermittently dosed epinephrine, antihistamines, and steroids. As discussed in more detail below, some such patients are particularly triggered by a wide range of medication excipients, making it challenging for them to tolerate trials of any adulterated (non-pure) medications, and yet some modicum of stability is required to pursue medication trials in such patients.

Table 4 Case series and clinical therapeutic trials in systemic mastocytosis and mast cell activation syndrome

| Compound | Number of patients included in the study or case series | References |
|-------------------------------------|---|----------------------------|
| H₁-antihistamines | | |
| Rupatadine | 30 | Siebenhaar et al. 2013 |
| Azelastine vs. chlorpheniramine | 15 | Friedman et al. 1993 |
| Ketotifen vs. hydroxyzine | 8 | Kettelhut et al. 1989 |
| Chlorpheniramine plus cimetidine | 8 | Frieri et al. 1985 |
| Continuous diphenhydramine infusion | 10 | Afrin 2015 ^a |
| Mast cell stabilizer | | |
| Cromoglicic acid (cromolyn) | 5 | Soter et al. 1979 |
| | 11 | Horan et al. 1990 |
| | 4 | Mallet et al. 1989 |
| | 8 | Frieri et al. 1985 |
| | 2 | Welch et al. 1983 |
| | 2 | Zachariae et al. 1981 |
| Tranilast | 2 | Katoh et al. 1996 |
| Kinase inhibitors | | |
| Imatinib (STI571) | 14 | Droogendijk et al. 2006 |
| | 20 | Vega-Ruiz et al. 2009 |
| | 22 | Lim et al. 2009 |
| | 17 | Pagano et al. 2008 |
| | 12 | Pardanani et al. 2003 |
| | 5 | Heinrich et al. 2008 |
| | 3 | Hennessy et al. 2004 |
| Nilotinib (AMN107) | 61 | Hochhaus et al. 2015 |
| Dasatinib (BMS-354825) | 33 | Verstovsek et al. 2008 |
| | 4 | Purtill et al. 2008 |
| Midostaurin (PKC412) | 9 | Papayannidis et al. 2014 |
| | 11 | Knapper et al. 2011 |
| | 22 | Chandesris et al. 2014 |
| | 89 | Gotlib et al. 2014 |
| | 14 | Strati et al. 2015 |
| Masitinib | 25 | Paul et al. 2010 |
| Cytostatic agents | | |
| Hydroxyurea | 26 | Lim et al. 2009 |
| | 5 | Afrin 2013 ^a |
| Cladribine (2-chlorodeoxyadenosine) | 22 | Lim et al. 2009 |
| | 10 | Kluin-Nelemans et al. 2003 |
| | 4 | Pardanani et al. 2004 |
| | 3 | Pagano et al. 2008 |
| | 68 | Barete et al. 2015 |

Table 4 (continued)

| Compound | Number of patients included in the study or case series | References |
|--|---|--------------------------------------|
| Immunomodulation | | |
| Interferon- α | 20 | Casassus et al. 2002 |
| | 5 | Hauswirth et al. 2004 |
| | 10 | Laroche et al. 2011 |
| | 40 | Lim et al. 2009 |
| | 8 | Pagano et al. 2008 |
| | 6 | Giraldo Castellano et al. 1998 |
| | 9 | Hennessy et al. 2004 |
| | 3 | Worobec et al. 1996 |
| Thalidomide | 16 | Gruson et al. 2013 |
| IgE antibody | | |
| Omalizumab | 4 | Molderings et al. 2011b ^a |
| | 2 | Carter et al. 2007 |
| | 2 | Lieberoth and Thomsen 2015 |
| β-Sympathomimetics | | |
| Isoprenaline, terbutaline | 5 | van Doormaal et al. 1986 |
| Cyclooxygenase inhibitor | | |
| Acetylsalicylic acid | 4 | Butterfield and Weiler 2008 |
| | 20 | Butterfield 2009 |

^a It indicates clinical trials performed with patients with mast cell activation syndrome

Diphenhydramine is a well-tolerated histamine H₁ receptor blocker (that among other non-threatening adverse effects can cause dizziness and an increase in appetite) which can quickly suppress MC activation and is used to treat allergic reactions and anaphylaxis. However, its half-life is as short as 1 h (www.drugbank.ca/drugs/DB01075). Intermittently dosed, though, its initial therapeutic serum level rapidly declines to subtherapeutic levels and the patient seesaws into yet another flare. The safety of continuous diphenhydramine infusion was established in trials of the “BAD” regimen (diphenhydramine [Benadryl], lorazepam [Ativan], and dexamethasone) in refractory chemotherapy-induced emesis in adult and pediatric patients (Dix et al. 1999; Jones et al. 2007). In a small series of ten MCAS patients suffering almost continuous anaphylactoid/dysautonomic flares, continuous diphenhydramine infusion at 10–14.5 mg/h appeared effective in most patients at dramatically reducing flare rates and appeared safely sustainable at stable dosing for at least 21 months (Afrin 2015). Stabilization has enabled successful trials of other helpful medications, but no patient has yet successfully stopped continuous diphenhydramine infusion.

Table 5 First-line drugs which can potentially be used in the treatment of mast cell (MC) activation disease and their target location and mechanisms of action

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | References |
|---|--|-------------------|------------------------------|---------------------|--|
| First-line drugs | | | | | |
| H ₁ -antihistamines (preferably of the second and third generations) | Block mutual activation of mast cells via H ₁ -histamine receptors; antagonize H ₁ -histamine receptor-mediated symptoms | | X | X | Church and Gradidge 1980 Valent et al. 2007R Picard et al. 2013R Nurmatov et al. 2015 Siebenhaar et al. 2013 Escribano et al. 2006R |
| H ₂ -antihistamines | Block mutual activation of mast cells via H ₂ -histamine receptors; antagonize H ₂ -histamine receptor-mediated symptoms | | X | X | Valent et al. 2007R Escribano et al. 2006R |
| Cromoglicic acid (also known as cromolyn) | GPR35; modulation of chloride current | | X | X | Soter et al. 1979 Valent et al. 2007R Yang et al. 2010 Edwards et al. 2011 Edwards and Hagberg 2010 Zhang et al. 2016 Escribano et al. 2006R |
| Vitamin C | Increased degradation of histamine; decrease of histamine formation by inhibition of histidine decarboxylase | | X | X | Hagel et al. 2013 Johnston et al. 1992 Uchida et al. 1989 Chatterjee et al. 1975 |

As a rule, these drugs should be used in combination to achieve a sufficient reduction of MC activity. All drugs should be tested for tolerance in a low single dose before therapeutic use, if their tolerance in the patient is not known from an earlier application. A precondition for therapeutic success is the avoidance of identifiable triggers of MC activation; in this context, parallel to the beginning of drug therapy, gluten, cow milk protein, and baker's yeast should be omitted from the diet for 3–4 weeks

R review article (further references therein)

Acute and chronic immunosuppressive therapies

Though typically not first-line, acute and chronic immunosuppressive therapies can be considered (Fig. 3; Table 7) and may be particularly appropriate for patients possibly manifesting an autoimmune component of the disease as might be suggested by the presence, for example, of anti-IgE or anti-IgE-receptor antibodies. Glucocorticoids may exert beneficial effects in MCAD, including a decrease in production of stem cell factor (SCF, and possibly other cytokines) and a decrease in MC activation, by various mechanisms which have been extensively reviewed by Oppong et al. 2013. Glucocorticoids at doses >20 mg prednisone equivalent per day are frequently needed to effectively control otherwise refractory acute (and chronic) symptoms. Their chronic toxicity profile is disadvantageous for long-term use, but such toxicities have to be accepted in some cases. The influence of azathioprine, methotrexate, ciclosporine, hydroxyurea, and tamoxifen on MC activity can vary from no to moderate effect depending on individual disease factors. As in therapy of rheumatoid arthritis, azathioprine and methotrexate can be used in daily doses

lower than those used in cancer or immunosuppressive post-transplant therapy. Effective MCAD therapy with ciclosporine requires doses as high as those used in transplantation medicine (M. Raithel, personal communication). Methotrexate has to be administered parenterally to be effective (unpublished observation, G.J. Molderings), and in the risk-benefit analysis, a possible non-immunologic histamine release from MCs (Estévez et al. 1996) has to be considered. Hence, use of the compound should be limited to MCAD with methotrexate-sensitive comorbidities (e.g., rheumatoid arthritis and vasculitis).

Recently, the humanized anti-IgE murine monoclonal antibody omalizumab has been described in multiple case reports as safe and effective in MCAD (e.g., Molderings et al. 2011b; Kontou-Fili et al. 2010; Bell and Jackson 2012; Kibsgaard et al. 2014), though a definitive trial has yet to be conducted. Since treatment with omalizumab has an acceptable risk-benefit profile, it should be considered in cases of MCAD resistant to at least a few lines of therapy. The drug's expense likely consigns it to third-line (or later) treatment (Table 7). If elevated prostaglandin levels induce symptoms such as

Table 6 Symptomatic treatment (orally as needed) in MCAD (modified from Molderings et al. 2014)

| |
|---|
| Colitis ⇒ budesonide; for some days, prednisone >20 mg/day |
| Diarrhea ⇒ c(h)olestyramine; nystatin; montelukast; 5-HT ₃ receptor inhibitors (e.g. ondansetron); incremental doses of acetylsalicylic acid (50–350 mg/day; extreme caution because of the possibility to induce mast cell degranulation); in steps test each drug for 5 days until improvement of diarrhea |
| Colicky abdominal pain due to distinct meteorism ⇒ metamizole; butylscopolamine |
| Angioedema ⇒ tranexamic acid; icatibant |
| Nausea ⇒ dimenhydrinate; lorazepam; 5-HT ₃ receptor inhibitors; NK1 antagonists such as aprepitant |
| Respiratory symptoms (mainly due to increased production of viscous mucus and obstruction with compulsive throat clearing) ⇒ leukotriene receptor blockers such as montelukast; if in a country available, leukotriene synthesis inhibitors such as zileuton; urgent: short-acting β-sympathomimetic |
| Gastric complaints ⇒ proton-pump inhibitors (de-escalating dose-finding) |
| Osteoporosis, osteolysis, bone pain ⇒ bisphosphonates (vitamin D plus calcium application is second-line treatment in MCAD patients because of limited reported success and an increased risk for developing kidney and ureter stones); calcitonin; teriparatide (with caution; cases of cholestatic liver failure due to this drug have been reported); anti-RANKL drugs such as denosumab (dental clearance is required prior to treatment with bisphosphonates and anti-RANKL therapies due to risk for potentially severely morbid osteonecrosis of the jaw in patients with poor dentition or recent invasive dental work) |
| Non-cardiac chest pain ⇒ when needed, additional dose of a H ₂ -histamine receptor antagonist; also, proton-pump inhibitors for proven gastroesophageal reflux |
| Tachycardia ⇒ AT ₁ -receptor antagonists; ivabradine |
| Neuropathic pain and paresthesia ⇒ α-lipoic acid |
| Itches ⇒ palmitoylethanolamine-containing care products; cromolyn-containing ointment |
| Rheumatoid symptoms ⇒ COX2 inhibitors such as etoricoxib or celecoxib; paracetamol |
| Anemia ⇒ in iron-deficiency anemia, iron supplementation (whether oral or parenteral) must be given cautiously due to risk for potentially intense mast cell activation; alternatively, red blood cell transfusion should be considered |
| Interstitial cystitis ⇒ pentosan, amphetamines |
| Sleep-onset insomnia/sleep-maintenance insomnia ⇒ triazolam |
| Conjunctivitis ⇒ exclusion of a secondary disease; otherwise preservative-free eye drops with H ₁ -antihistamine, cromolyn, ketotifen, or glucocorticoid for brief courses |
| Hypercholesterolemia ⇒ (probably due to inhibition of transport into the cells, thus independent of diet) >300 mg/dL therapeutic trial with HMG-CoA reductase inhibitor atorvastatin |

persistent flushing, inhibition of cyclooxygenases by incremental doses of acetylsalicylic acid (ASA; 50–350 mg/day) may be used with extreme caution, since ASA can induce MC

degranulation probably due its chemical property as an organic acid. The leukotriene antagonist montelukast (possibly more effective at twice-daily dosing; personal observation,

Fig. 3 Suggested treatment options for mast cell activation disease. All drugs should be tested for tolerance in a low single dose before therapeutic use, if their tolerance in the patient is not known from an earlier application. For further details of indication, see text




Table 7 Second- and third-line drugs which can potentially be used in the treatment of mast cell activation disease and their target location and mechanisms of action

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | References |
|------------------------------------|---|-------------------|------------------------------|---------------------|--|
| Second-line drugs | Immunosuppressive drugs | | | | |
| Azathioprine | Multiple targets | | X | X | Nolte and Stahl Skov 1988, Own unpublished data |
| Ciclosporine | Calcineurin inhibitor | | X | X | Kurosawa et al. 1999, Broyd et al. 2005, Trojan and Khan 2012, Own unpublished data |
| Glucocorticoids | Multiple targets | (X) | X | X | Zen et al. 2011R |
| Hydroxyurea | Multiple targets | X | | X | Lim et al. 2009, Afrin 2013 |
| Tamoxifen | Precise mechanism of action in MCAD unknown | X | X | In single cases | Butterfield and Chen 2016, Duffy et al. 2003; |
| Methotrexate | Multiple targets | | ? | X | Sagi et al. 2011, Vrugt et al. 2000 |
| Third-line drugs | | | | | |
| Omalizumab | Anti-IgE antibody | | | X | Molderings et al. 2011b Bell and Jackson 2012; Kibsgaard et al. 2014 Kontou-Fili et al. 2010 |
| Etoricoxib Acetylsalicylic acid | COX-inhibitors | | | X | Butterfield and Weiler 2008 Breslow et al. 2009 Butterfield 2009 |
| Montelukast | Antagonist at cys-LT ₁ receptors | | | X | Tolar et al. 2004 Cikler et al. 2009 Breslow et al. 2009 Turner et al. 2012 |
| Zileuton | 5-Lipoxygenase inhibitor | | | X | Rodriguez et al. 2011 |

R review article (further references therein)

L.B. Afrin) and the 5-lipoxygenase inhibitor zileuton may be useful adjuvants in people with MCAD, particularly in those with refractory gastrointestinal and urinary symptoms (Tolar et al. 2004; Turner et al. 2012; Akhavein et al. 2012).

Studies of kinase inhibitors, both on-market (e.g., imatinib, nilotinib, dasatinib) and experimental (e.g., midostaurin, masitinib), have yielded variable responses in SM ranging from no response to partial or even complete responses (Fig. 3; Table 8). As with all drugs used in therapy of MCAD, their therapeutic success seems to be strongly dependent on the individual patient, again underscoring the observed mutational heterogeneity of the disease. In formal studies in SM patients, although some kinase inhibitors reduced MC burden as reflected by histological normalization in bone marrow and improved laboratory surrogate markers (e.g., tryptase level in blood), at best only partial improvement of mediator-related symptoms was achieved (Droogendijk et al. 2006; Gotlib et al. 2008; Verstovsek et al. 2008; Vega-Ruiz et al. 2009). There has been repeated suggestion that symptoms in MCAD may be due more to mediator release from normal MCs secondarily activated by pathologically overactive, mutated MCs (Galli and Costa 1995; Rosen and Goetzl 2005; Boyce 2007; Kaneko et al. 2009; Fig. 2 in Molderings et al.

2014), helping to explain why intensity and pattern of symptoms do not correlate with degree of MC proliferation and infiltration (Topar et al. 1998; Hermine et al. 2008; Broesby-Olsen et al. 2013; Erben et al. 2014; Quintás-Cardama et al. 2013). Distinction in pathways in the MC which promote MC proliferation vs. mediator production/release may explain why kinase inhibitors reduce MC burdens and MC-driven symptoms to different degrees (Droogendijk et al. 2006; Gotlib et al. 2008; Verstovsek et al. 2008; Vega-Ruiz et al. 2009; Table 8). However, in some case reports, kinase inhibitors have been significantly effective at relieving symptoms. Thus, in spite of potential serious adverse effects of these drugs, a therapeutic trial may be justified in individual cases at an early stage. Partial and complete responses have been reported with some of these agents in MCAS too (e.g., Afrin 2010, 2011, 2012, 2015; Afrin et al. 2015a). Dosing of the kinase inhibitors in the individual often is considerably lower than how such drugs are dosed for other applications (e.g., imatinib, sunitinib; Afrin et al. 2015a). Possibly due to the causative mutations in multiple genes leading to simultaneous activation of multiple intracellular pathways, multitargeted kinase inhibitors such as midostaurin and sunitinib may be more effective than

Table 8 Kinase inhibitors which can potentially be used as fourth-line drugs in the treatment of mast cell activation disease and their target location and mechanisms of action

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | References |
|-------------------|--|-------------------|------------------------------|-----------------------------|---|
| Fourth-line drugs | Inhibitors of tyrosine kinases and other kinases | | | | |
| Imatinib | KIT (excluding D816X), PDGFR, Bcr-Abl, Arg/Abl2, DDR-1 | X | (X) | X | Pardanani et al. 2003 Droogendijk et al. 2006 Lim et al. 2009 Vega-Ruiz et al. 2009 Aman et al. 2012 Vaali et al. 2012 Quintás-Cardama et al. 2011R Marton et al. 2015 |
| Nilotinib | KIT, PDGFR, Bcr-Abl | X | | (X) | Hochhaus et al. 2006 Quintás-Cardama et al. 2011R Hochhaus et al. 2015 El-Agamy 2012 |
| Dasatinib | KIT, BCR-ABL1, Lyn, Btk, Tec | X | | (X) | Verstovsek et al. 2008 Hantschel et al. 2007 Gleixner et al. 2011 Quintás-Cardama et al. 2011R |
| Sunitinib | VEGFR, PDGFR, KIT, FLT3, RET, CSF1R, SRC, 313 potential kinase targets | X | X | X | Afrin et al. 2015a Yamaki and Yoshino 2012 Papaetis and Syrigos 2009 Bairlein 2010 |
| Masitinib | KIT, PDGFR α , Lck, LYN, FGFR3, FAK | X | | X | Marech et al. 2014 Moussy and Kinet 2014 Paul et al. 2010 Quintás-Cardama et al. 2011R |
| Midostaurin | PKC, FLT3, KIT, PDGFR, VEGFR2 | X | X | X | Gotlib et al. 2014 Papayannidis et al. 2014 Knapper et al. 2011 Quintás-Cardama et al. 2011R |
| Ponatinib | Bcr-Abl, KIT, FLT3, FGFR1, PDGFR α , Lyn | X | | | Jin et al. 2014 Gleixner et al. 2013 |
| Bafetinib | KIT (excluding D816X), Abl, Lyn | X | | | Peter et al. 2010a |
| Bosutinib | Lyn, Btk | X | | In ASM patients ineffective | Gleixner et al. 2011 Randall et al. 2015 |

R review article (further references therein)

drugs which selectively downregulate only one intracellular pathway.

In the mastocytosis patient with significant MC burden and/or an aggressive clinical course, cytoreductive drugs are prescribed (Lim et al. 2009; Valent et al. 2010). Unfortunately, effective cytoreductive therapies in SM presently are few in number and typically offer only modest response rates, qualities, and durations. Cytoreductive options include interferon- α and 2-chlorodeoxyadenosine (cladribine, 2-CdA; Fig. 3 and Table 9). Interferon- α is frequently combined with prednisone and is commonly used as cytoreductive therapy for aggressive SM. It ameliorates mastocytosis-related organopathy in a proportion of cases but can be associated with considerable adverse effects (e.g., flu-like symptoms, myelosuppression, depression, hypothyroidism), which may

limit its use in MCAD (Simon et al. 2004; Butterfield 2005). PEGylated interferon- α has been shown to be as efficacious as and less toxic than the non-PEGylated form in some myeloproliferative neoplasms, but it has not been specifically studied in MCAD. 2-Chlorodeoxyadenosine is generally reserved for last-choice treatment of patients with aggressive SM who are either refractory or intolerant to interferon- α . Potential toxicities of 2-CdA include significant and potentially prolonged myelosuppression and lymphopenia with increased risk for opportunistic infections.

Last resorts

Polychemotherapy, including intensive induction regimens of the kind used in treating acute myeloid leukemia, as well as

Table 9 Last-choice drugs which can potentially be used in the treatment of mast cell activation disease and their target location and mechanisms of action. R-review article (further references therein)

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | References |
|----------------------|--------------------------------------|-------------------|------------------------------|---------------------|---|
| Last-choice drugs | | | | | |
| Interferon- α | Multiple targets | X | | (X) | Simon et al. 2004 Casassus et al. 2002 Hauswirth et al. 2004 Butterfield et al. 2005 Butterfield 2005R Yoshida et al. 2009 Lim et al. 2009 Quintás-Cardama et al. 2011R |
| Cladribine | Nucleoside analog | X | X | X | Tefferi et al. 2001 Kluin-Nelemans et al. 2003 Pardanani et al. 2004 Lim et al. 2009 Böhm et al. 2010 Radojković et al. 2011 Quintás-Cardama et al. 2011R Lock et al. 2015 Barete et al. 2015 |

high-dose therapy with stem cell rescue, are approaches restricted to rare, selected patients. Allogeneic stem cell transplantation sometimes yields remissions in mastocytosis long thought impermanent (Spyridonidis et al. 2004; Nakamura et al. 2006; Bae et al. 2013; Gromke et al. 2013), though recent data may offer new hope (Ustun et al. 2014).

Investigational drugs

There are several drugs approved for indications other than MCAD which already have been successfully used in isolated cases with MCAD (Table 10). In cases of unsuccessful first- to fourth-line therapy, these compounds may be considered as treatment options.

A variety of drugs have been shown to inhibit MC growth, to decrease MC mediator release, and/or to relieve mediator-induced symptoms in *in vitro* and *in vivo* animal models (Table 11). Some of these drugs are approved for certain indications (such as ambroxol, statins, mefloquine, and ruxolitinib) and, thus, may be used (if accessible given financial considerations for some agents) if MCAD patients suffer from both the disorder of indication (e.g., hypercholesterolemia—statins, mucous congestion—ambroxol, polycythemia vera—ruxolitinib) and MCAD. An important question is what the role of the other compounds without approved indications should be in clinical practice. There are several challenges that may hamper the clinical introduction of novel targeted therapies in general. Some of these challenges include inherent problems in the translation of preclinical findings to the clinic, the presence of multiple coactive deregulated pathways in the disease, and questions related to the optimal design of clinical

trials (e.g., eligibility criteria and endpoints). In particular, the testing of novel targeted treatment in an isolated fashion may be problematic and may in fact underestimate the effectiveness of these novel compounds. It is reasonable to assume that combination therapy will be the key to target parallel critical pathways.

General considerations on drug treatment of MCAD

Although no biomarkers of symptomatology or therapeutic response are yet validated, the tolerability and efficacy of most therapies tried in MCAD (starting, and escalating in dosage and composition, cautiously) become clinically evident within 1–2 months. Modest experiments with alternative dosages and/or dosing frequencies are not unreasonable. Therapies clearly shown clinically helpful should be continued; therapies not meeting this high bar should be halted to avoid the troublesome polypharmacy that can easily develop in such patients. With no predictors of response yet available, a cost-based approach to sequencing therapeutic trials in a given patient seems reasonable. It is not even clear yet that medications targeted at mediators found elevated in diagnostic testing (e.g., antihistamines in patients with elevated histamine, non-steroidal anti-inflammatory drugs in patients with elevated prostaglandins, leukotriene inhibitors in patients with elevated leukotrienes) are reliably effective, again perhaps unsurprising given the multitude of MC mediators and the complexity of the signaling networks dysregulated by the multiple mutations in MC regulatory elements present in most MCAD patients. Successful regimens appear highly personalized.

Table 10 Drugs successfully (or not) used off-label to treat isolated cases of mast cell activation disease

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | References |
|---|---|-------------------|------------------------------|----------------------------|--|
| Investigational drugs | | | | | |
| Thalidomide | Precise mechanism of action unknown | | | X | Damaj et al. 2008 Gruson et al. 2013 |
| Lenalidomide | | | | No effect | Kluin-Nelemans et al. 2009 |
| Flavonoids (e.g., luteolin, quercetin, genistein) | Multiple | X | (X) | (X) | Alexandrakis et al. 2003 Kempuraj et al. 2006 Min et al. 2007 Finn and Walsh 2013R Weng et al. 2012 Lee et al. 2015 Weng et al. 2015 |
| Miltefosine | Raft modulator | | X | (X) | Weller et al. 2009 Maurer et al. 2013R |
| Mepolizumab | IL-5 antibody | X | | | Otani et al. 2012 |
| Rituximab | CD20 antibody | | | X | Borzutzky et al. 2014 |
| Ruxolitinib | JAK | X | | X | Yacoub and Prochaska 2016 Kvasnicka et al. 2014 |
| Cannabinoids | Agonists at the cannabinoid receptors | | | X | De Filippis et al. 2008 Frenkel et al. 2015 Own unpublished experiences |
| Methylene blue | Guanylyl cyclase inhibitor | | | Anaphylaxis treatment | Rodrigues et al. 2007 Evora and Simon 2007R |
| Pimecrolimus | Calcineurin inhibitor | X | | Cutaneous symptoms; (mice) | Ma et al. 2010 Correia et al. 2010 |
| Everolimus | mTOR | | | no effect | Parikh et al. 2010 |
| Ribavirin | Possibly suppression of activated retroviral elements in the genome which may be involved in the development of the somatic mutations in KIT and other proteins | | X | X | Marquardt et al. 1987 Molderings 2016 Own unpublished experiences |

R review article (further references therein)

Multiple simultaneous (or nearly so) changes in the medication regimen are discouraged since such can confound identification of the specific therapy responsible for a given improvement (or deterioration). Ineffective or harmful agents should be stopped promptly. Prescribers should be aware that although rapid demonstration of intolerance of a new medication (or a new formulation of a previously well-tolerated medication) often suggests excipient reactivity as further discussed below, some active drug molecules themselves (e.g., cromolyn) sometimes cause an initial symptom flare which usually soon abates. Temporary waiver of gluten-, yeast-, and cow milk protein-containing foods during the initial 3–4 weeks of drug therapy can improve the response rate (Biesiekierski et al. 2011; Rodrigo et al. 2013; own unpublished experiences). When MCAD is suspected, therapies that strongly activate

the immune system (e.g., vaccinations with live vaccines or autohemotherapy) must be given with caution (especially if similar therapies were previously already poorly tolerated), as such interventions sometimes dramatically worsen MCAD acutely and/or chronically.

Any drug can induce intolerance symptoms in the individual MCAD patient. In some MCAD patients, the disease creates such remarkable states of not only constitutive MC activation but also aberrant MC reactivity that such patients unfortunately experience a great propensity to react adversely to a wide variety of medication triggers. Those MCAD patients begin demonstrating (either acutely or subacutely) odd/unusual/weird/strange/bizarre/unexpected symptoms soon after beginning new medications. It is very important to note that such patients often demonstrate even a greater propensity to react to

Table 11 Investigational drugs which might have activity against mast cell activation disease since they induce apoptosis of mast cells and/or suppress mast cell mediator release in vitro and/or in vivo

| Investigational drugs | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | Investigated in vitro | Investigated in vivo | References |
|--|---|-------------------|------------------------------|---------------------|--|----------------------|--|
| ABT-737 {(R)-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-{4-[4-(4'-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-3-nitro-benzenesulfonamide} | BH3 mimetic | X | | | Murine BMMC, human cord blood-derived MCs, C57 MC line, MC/9 MC line | Mice | Karlberg et al. 2010b |
| 17-Allyl amino-17-demethoxygeldanamycin, Ganetespib (STA-9090) | Binding to heat shock protein 90 | X | | | HMC-1, canine BMIMC, C2 MC line, BR canine mastocytoma cell lines | | Fumo et al. 2004 Lin et al. 2008 |
| Ambroxol | Multiple | | X | | Human MCs | | Gibbs et al. 1999 |
| Amitriptyline, clomipramine, maprotiline | Yet to be defined in MCAD | | X | | | Male Wistar rats | Gurgel et al. 2013 Clemens et al. 2011 |
| Benzodiazepines | Yet to be defined | (X) | X | X | | | Molderings et al. 2013b; Dueñas-Laita et al. 2009; Bidri et al. 1999; Fujimoto et al. 2005; Suzuki-Nishimura et al. 1989; Hoffmann et al. 2013 |
| BI 2536 {(R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide} | Polo-like kinase-1 | X | | | HMC-1, primary human neoplastic MCs | | Peter et al. 2011 |
| BLU-285 (chemical structure not yet published) | KIT | X | | | HMC-1,2, P815 mouse mastosarcoma cells | | Evans et al. 2015 |
| Botulinum toxin A | Cleavage of the SNARE proteins | X | X | | | SD rats | Park 2013 |
| Butaprost | EP ₂ receptor agonist | X | X | | Human lung MCs | | Kay et al. 2006 |
| Cerivastatin, fluvastatin, atorvastatin | Unknown in MCAD | X | X | | Primary human MCs, HMC-1, P815 | | Krauth et al. 2006 Paez et al. 2015 |
| Chemokine receptor antagonists | Targeting activating chemokine receptors expressed on MCs | | X | | | Mice | Koelink et al. 2012R |
| Cinnamaldehyde | Signaling molecules, e.g., ERK1/2, JNK, p38, Akt | | X | | Human MCs, RBL-2H3 cells | | Hagenlocher et al. 2015 |
| Combined arginine and glutamine | Multiple | | X | | Human intestinal MCs | | Bibi et al. 2014R Lechowski et al. 2013 |

Table 11 (continued)

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | Investigated in vitro | Investigated in vivo | References |
|--|---|-------------------|------------------------------|---------------------|---|--------------------------------------|---|
| Coumarines (scopoletin) | Yet to be defined in MCAD | | X | | HMC-1 | | Moon et al. 2007 Finn and Walsh 2013R |
| CRA1000 (<i>N</i> -ethyl-4-[4-(3-fluorophenyl)-3,6-dihydro-2 <i>H</i> -pyridin-1-yl]-6-methyl- <i>N</i> -(2-methylsulfanyl)-4-propan-2-ylphenyl)pyrimidin-2-amine} | Non-peptidic corticotropin-releasing factor antagonist | | X | | | Mouse dermal MCs | Shimoda et al. 2010 |
| Crenolanib | FLT3 | X | | | HMC-1, p815, MCs from SM patients | | Schittenhelm et al. 2014 |
| Curcumin | Multiple | | X | | HMC-1, murine BMMC | BALB/c mice | Back et al. 2003 Kinney et al. 2015 |
| Demethylating agents (5-azaacytidine, 5-aza-2'-deoxycytidine) | DNA methylation | X | | (X) | HMC-1 | | Krug et al. 2010 Meeran et al. 2010R |
| EXEL-0862 (WO2004050681 A2) | KIT, STAT3 | X | | | HMC-1 | | Pan et al. 2007 |
| Fedratinib (TG101348) | JAK2 inhibition | X | | | HMC-1 | | Lasho et al. 2010 |
| GLC756 {(3 <i>R</i> ,4 <i>R</i> ,10 <i>aR</i>)-1,2,3,4,4 <i>a</i> ,5,10,10 <i>a</i> -octahydro-6-hydroxy-1-methyl-3-[(2-pyridyl)-thio methyl]-benzo [g]quinolinehydrochloride)} | Dopamine D ₁ and D ₂ receptor agonist | | X | | RBL-2H3 cells | | Laengle et al. 2006 |
| Gly-Phe-CHN ₂ , PZ610, PZ709, PZ889 (chemical structures not yet published) | Dipeptidyl/peptidase-1 inhibitors | | | | LAD2 MC | | El-Feki et al. 2011 |
| Histamine H ₄ -receptor agonist | Histamine H ₄ -receptor | | X | X | HMC-1, murine MCs | Ex vivo guinea pig and murine hearts | Aldi et al. 2014 |
| Histone deacetylase inhibitors: vorinostat, AR-42 { <i>N</i> -hydroxy-4-[[[(2 <i>S</i>)-3-methyl-2-phenylbutanoyl]amino]benzamide} | Histone deacetylase | X | | | HMC-1, 2, primary human MCs, murine, and canine MCs | | Mühlberg et al. 2009 Hadziusufovic et al. 2010 Meeran et al. 2010R Abdulkadir et al. 2015 Lin et al. 2010 |
| Hypothemycin | Inhibition of KIT and Btk | | X | | Human MCs | Mice | Jensen et al. 2008 |
| IMD-0354 { <i>N</i> -[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide} | NF-κB inhibitor | X | | | HMC-1 | | Tanaka et al. 2005 |
| JTE-052 {3-[(3 <i>R</i> ,4 <i>R</i>)-4-methyl-3-[methyl-(7 <i>H</i> -pyrrolo[2,3- <i>d</i>]pyrimidin-4-yl)-amino]-piperidin-1-yl]-3-oxo-propionitrile mono citrate} | JAK1, 2, 3 inhibitor, Tyk2 inhibitor | | X | | Human MCs | DBA/1J mice, Lewis rats | Tanimoto et al. 2015 |

Table 11 (continued)

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | Investigated in vitro | Investigated in vivo | References |
|---|---|-------------------|------------------------------|---------------------|---|----------------------|---|
| Mefloquine | Permeabilization of secretory granules | X | | | Human and murine MCs | | Paivandy et al. 2014 |
| Mylotarg (gemtuzumab ozogamicin) | CD-33 targeting drug | X | | | HMC-1, human cord blood-derived MCs | | Krauth et al. 2007 |
| Neramexane | Possibly NMDA antagonist | | X | | HMC-1 cells | | Kurzen 2009 |
| Obatoclox | BH3 mimetic | X | | | HMC-1, human neoplastic BMMC | | Aichberger et al. 2009 |
| ONO-4053 (chemical structure not yet published) | Prostaglandin receptor DP1 antagonist | X | | | Human BMMC | | Yamaguchi et al. 2016 |
| 8-OH-DPAT (7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol) | 5-HT _{1A} receptor | No effect | X | | | | Ritter et al. 2012 |
| Palmitoylethanolamide | PPAR- α , cannabinoid receptors, potassium channels, TRPV1 | | | X | rat peritoneal MCs | | Facci et al. 1995 Maffei-Raso et al. 2014R |
| PD180970 {6-(2,6-dichlorophenyl)-2-(4-fluoro-3-methylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one} | KIT, Bcr-Abl, PDGFR | X | | | HMC-1, P815 MCs | | Corbin et al. 2004 |
| Phosphodiesterase inhibitors | Phosphodiesterase | | X | | Human lung MCs, rat MCs | Wistar rats | Lau and Kam 2005; Eskandari et al. 2015 Babaei and Bayat 2012 |
| Phosphatidylethanolamine, phosphatidylserine | CD300a | X | | | Human cord blood-derived MCs, human lung MCs, murine BMMC | | Bachelet et al. 2005 Simhadri et al. 2012 |
| Prostaglandin D ₂ receptor antagonists | CRTH2 | | | X | | | Harvima et al. 2014R |
| Proteases inhibitors | Trypsin, chymase, cathepsins, carboxypeptidase | | | X | Human and murine MCs | Mice | Caughey 2016R Harvima et al. 2014R |
| Rapamycin | mTOR pathway inhibitor | X | | | HMC-1 | | Chan et al. 2013 |
| RNAi | RNA interference against <i>KIT</i> RNA | X | | | HMC-1 | | Ruano et al. 2010 |
| Rosiglitazone, pioglitazone | PPAR γ | | X | | Murine BMMC | | Tachibana et al. 2008 |
| Siramessine | Sigma-2 receptor agonist | X | | | Human and murine MCs | | Spirkoski et al. 2012 |
| Sitagliptin | Dipeptidylpeptidase-4 inhibitor | | X | | Rat peritoneal MCs | | Nader 2011 1845 |
| Somatostatin | Somatostatin receptors | | | X | | | Tang et al. 2005 |
| Syk kinase inhibitors | Syk kinase | | X | | Human, murine, and rat MCs; RBL-2H3 | Wistar rats | Matsubara et al. 2006 Finn and Walsh 2013 |
| Tandutinib (MLN518) | KIT, STAT3 | X | | | HMC-1, P815 MCs | | Corbin et al. 2004 |

Table 11 (continued)

| | Target location/mechanisms of action | Growth inhibition | Decrease of mediator release | To relieve symptoms | Investigated in vitro | Investigated in vivo | References |
|--|--------------------------------------|-------------------|------------------------------|---------------------|------------------------|----------------------|--|
| Tetracyclines | Multiple | X | | X | Rat serosal MCs, HMC-1 | Human | Sandler et al. 2005 Joks and Durkin 2011R |
| α -Tocopherol | Multiple | X | | | HMC-1 | | Kempna et al. 2004 Ruano et al. 2010 |
| Tranilast | Yet to be defined | | X | (X) | Rat peritoneal MC | Rats; rabbits | Adachi et al. 1999 Cooper et al. 2007 Baba et al. 2016 |
| Whi-P131 {4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol} | JAK3/STAT pathway inhibitor | X | | | HMC-1 | | Chan et al. 2013 Bibi et al. 2014R |

R review article (further references therein), MC mast cell, BMMC bone marrow-derived mast cells

Table 12 Compilation of drugs associated with a high risk of release of mediators from mast cells and their therapeutic alternatives (compiled from Mousli et al. 1994; Sido et al. 2014; Afrin et al. 2015b; McNeil et al. 2015)

| Substance group | Drugs with proven or theoretical high risk of mast cell activation | Therapeutic alternatives |
|--|---|--|
| Intravenous narcotics | Methohexital Phenobarbital Thiopental | Propofol Ketamine Etomidate Midazolam |
| Muscle relaxants | Atracurium Mivacurium Rocuronium | Cis-atracurium Vecuronium |
| Antibiotics | Cefuroxim Gyrase inhibitors Vancomycin | Roxithromycin |
| Selective dopamine- and norepinephrine reuptake inhibitors | Bupropion | Amitriptyline, doxepine, clomipramine, maprotiline |
| Selective serotonin reuptake inhibitors | All | |
| Anticonvulsive agents | Carbamazepine, topiramate | Clonazepam |
| Opioid analgesics | meperidine, morphine, codeine | remifentanyl, alfentanil, fentanyl, oxycodone, piritramid |
| Peripheral-acting analgesics | Acidic non-steroidal anti-inflammatory drugs such as ASS or ibuprofen | Paracetamol, metamizol |
| Local anesthetics | Amide-type: lidocaine articaine Ester-type: tetracaine, procaine | prefer amide-Type, e.g., bupivacaine |
| Peptidergic drugs | Icatibant, cetrorelix, sermorelin, octreotide, leuprolide | |
| X-ray contrast medium | Iodinated contrast medium Gadolinium chelate | Non-ionic contrast media: iohexol, iopamidol, iopromida, ioxilan, ioversol, idolatran, iodixanol |
| Plasma substitutes | Hydroxyethyl starch Gelatine | Albumin solution, 0.9 %-NaCl solution, Ringer's solution |
| Cardiovascular drugs | ACE inhibitors β -Adrenoceptor antagonists | Sartans, calcium channel antagonists, ivabradine, and much else |

medication excipients (i.e., fillers, binders, dyes, preservatives) than to the active ingredients. When the patient tries one or more alternative formulations of a medication with the same active ingredient but sharing as few as possible (preferably none) of the excipients in the offending formulation, the patient may discover the medication to be at least tolerable and perhaps even quite effective. Furthermore, such a scenario obviously provides the patient (and physician and pharmacist) a great opportunity to identify one or more of the specific excipients which are triggering abnormal reactivity in the patient's dysfunctional MCs, and it is those specific excipients—not the medication as a whole—that should be added to the patient's allergy list and screened against all present medications being taken by the patient and against all future medications proposed for the patient. An MCAD patient's physician would be wise to not assume, just because an excipient is very widely used in many medication products and appears innocuous and well tolerated in the vast majority of patients, that the same excipient will necessarily be tolerated well in MCAD patients (unpublished observation of the authors). Sometimes the specificity of the reaction is quite extraordinary. For example, patients who react to wood-based microcrystalline

cellulose might tolerate cotton-based microcrystalline cellulose without any difficulty at all, or vice versa. In some cases, the pharmacist is unable to identify alternative commercially available formulations sharing few to none of the excipients in the offending formulation, and in those cases, a compounding pharmacist may need to be engaged to identify/develop a custom-compounded formulation the patient can tolerate. (There can be geographic and financial challenges in accessing compounding pharmacies, though.) Occasionally, MCAD patients may be so remarkably reactive to such a wide range of excipients that they can only tolerate a given medication when provided as pure drug salt, reconstituted in water (without preservatives). Intolerance symptoms can be mediated by IgE antibodies, though this scenario appears to be rare since the symptoms are usually not ameliorated by the anti-IgE monoclonal antibody omalizumab (unpublished observation, G.J. Molderings). Alternatively, they may be mediated by IgG antibodies, raising the question of whether gamma globulin (if itself tolerable) might be a helpful adjunct therapy in such patients (perhaps by directly targeting the MC surface's IgG receptors or via

Table 13 Schematic summary of selected potential targets of pharmacological interventions in MCAD

| | |
|---|--|
| Targets of drugs located in the plasma membrane | |
| Histamine H ₁ receptor | H ₁ -antihistamines |
| Histamine H ₂ receptor | H ₂ -antihistamines |
| CB1/CB2 cannabinoid receptors | Cannabinoids |
| cysLTR1 leukotriene receptor | CysLTR1 antagonists, e.g., montelukast |
| β-Adrenoceptor | β-Sympathomimetics |
| EP ₂ receptor | EP ₂ receptor agonist, e.g., butaprost |
| Chemokine receptors | Chemokines |
| FcεRI | IgE antibody, e.g., omalizumab |
| FcγRIII | IgG |
| Siglec-8 | Siglec-8 ligand |
| CD300a | Phosphatidylethanolamine, phosphatidylserine |
| Targeting released mast cell mediators | |
| Trypsase | Trypsase inhibitor, e.g., nafamostat |
| Chymase | Chymase inhibitor, e.g., BCEAB (4-[1-[bis-(4-methyl-phenyl)-methyl]-3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid) |
| Cathepsin G | Cathepsin G inhibitor, e.g., RWJ355871 (β-ketophosphonate 1) |
| TNFα | Infliximab, adalimumab |
| IL-4 | Pascalizumab |
| IL-5 | e.g., mepolizumab |
| IL-6 | e.g., sirukumab |
| IL-17 | e.g., secukinumab |
| Intracellular inhibition of mediator formation | |
| Histamine | Histidine decarboxylase inhibition, e.g., by vitamin C |
| Leukotrienes | 5-Lipoxygenase inhibitors, e.g., zileuton |
| Prostaglandins | Cyclooxygenase inhibitors, e.g., acetylsalicylic acid, etoricoxib |
| Inhibition of cytosolic pathways | |
| Signaling pathways containing protein kinases | Inhibitors of protein kinases (see Table 8) |
| mTOR pathway | e.g., rapamycin, everolimus |
| Apoptotic pathways | Stimulation of apoptosis by, e.g., ABT-737, obatoclax |
| Intranuclear targets | |
| Histone deacetylase | Histone deacetylase inhibitors, e.g., vorinostat |
| DNA methylation | Demethylating agents, e.g., 5-azacytidine, 5-aza-2'-deoxycytidine |
| DNA | Nucleoside analog cladribine |

indirect pathways). Recently, a MC-specific receptor termed MRGPRX2 has been identified which appears to be crucially involved in pseudo-allergic drug reactions (McNeil et al. 2015; Seifert 2015).

Drugs which should not be used in MCAD

Several drugs have the ability to trigger MC mediator release. A compilation of drugs known to be associated with a high risk of release of mediators from MCs is given in Table 12. However, there often are therapeutic alternatives to these drugs (Table 12).

Conclusions and future perspectives

The therapeutic management of individuals with MCAD is complex and requires reviewing the entire spectrum of symptoms. The paucity of randomized, controlled studies makes treatment of refractory disease challenging and requires patience, persistence, and a methodical approach on the parts of both patient and managing provider(s). Delayed control of the symptoms may increase morbidity. Effective therapy often consists simply of antihistamines and MC-stabilizing compounds supplemented with medications targeted at specific symptoms and complications (Table 13). Current treatment options for refractory disease are based mainly on

observational studies and case reports. Until larger randomized, controlled trials become available to give more guidance on therapy for refractory disease, clinicians should use the available data in conjunction with their clinical expertise and the adverse effect profile of the available drugs to make treatment decisions. More research is certainly needed to better understand MCAD pathobiology, in particular to determine which deregulated genes contribute to a specific symptom or symptom cluster. The greatest challenge in translational research for the discovery of new rational therapies requires a highly interactive interdisciplinary approach engaging basic science labs and clinicians. Understanding of the key components might hasten the progress of novel treatment for all these devastating MCAD phenotypes.

Acknowledgments The publication of this article was financially supported by the *Förderclub Mastzellforschung e.V.*

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Abdulkadir H, Grootens J, Kjellander M, Hellström Lindberg E, Nilsson G, Ungerstedt J (2015) Histone deacetylase inhibitor SAHA mediates epigenetic silencing of KIT D816V mutated systemic mastocytosis primary mast cells and selective apoptosis of mutated mast cells. *Blood*;126: abstract 2834
- Adachi S, Maruyama T, Kondo T, Todoroki T, Fukao K (1999) The prevention of postoperative intraperitoneal adhesions by tranilast: N-(3',4'-dimethoxycinnamoyl)anthranilic acid. *Surg Today* 29:51–54
- Afrin LB (2010) Mast cell activation disorder masquerading as pure red cell aplasia. *Int J Hematol* 91:907–908
- Afrin LB (2011) Polycythemia from mast cell activation syndrome: lessons learned. *Am J Med Sci* 342:44–49
- Afrin LB (2012) Mast cell activation syndrome masquerading as agranulocytosis. *Mil Med* 177:113–117
- Afrin LB (2013) Utility of hydroxyurea in mast cell activation syndrome. *Exp Hematol Oncol* 2:28
- Afrin LB (2015) Utility of continuous diphenhydramine infusion in severe mast cell activation syndrome. *Blood* 126:5194 abstract
- Afrin LB, Molderings GJ (2014) A concise, practical guide to diagnostic assessment for mast cell activation disease. *World J Hematol* 3:1–17
- Afrin LB, Cichocki FM, Patel K, Molderings GJ (2015a) Successful treatment of mast cell activation syndrome with sunitinib. *Eur J Haematol* 95:595–597
- Afrin LB, Pöhlau D, Raitel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ (2015b) Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases. *Brain Behav Immun* 50:314–321
- Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P (2009) Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. *Blood* 114:5342–5351
- Akhavain A, Patel NR, Minoyappa PK, Glover SC (2012) Allergic mastocytic gastroenteritis and colitis: an unexplained etiology in chronic abdominal pain and gastrointestinal dysmotility. *Gastroenterol Res Pract* 2012:950582
- Akin C, Valent P, Metcalfe D (2010) Mast cell activation syndrome: proposed diagnostic criteria. *J Allergy Clin Immunol* 126:1099–1104
- Aldi S, Takano KI, Tomita K, Koda K, Chan NY, Marino A, Salazar-Rodriguez M, Thurmond RL, Levi R (2014) Histamine H4-receptors inhibit mast cell renin release in ischemia/reperfusion via PKC ϵ -dependent aldehyde dehydrogenase type-2 activation. *J Pharmacol Exp Ther* 349:508–517
- Alexandrakis MG, Kyriakou DS, Kempuraj D, Huang M, Boucher W, Seretakis D, Theoharides TC (2003) The isoflavone genistein inhibits proliferation and increases histamine content in human leukemic mast cells. *Allergy Asthma Proc* 24:373–377
- Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, Groeneveld AB, Vonk Noordegraaf A, van Hinsbergh VW, van Nieuw Amerongen GP (2012) Effective treatment of edema and endothelial barrier dysfunction with imatinib. *Circulation* 126:2728–2738
- Anand P, Singh B, Jaggi AS, Singh N (2012) Mast cells: an expanding pathophysiological role from allergy to other disorders. *Naunyn Schmiedeberg's Arch Pharmacol* 385:657–670
- Baba A, Tachi M, Ejima Y, Endo Y, Toyama H, Matsubara M, Saito K, Yamauchi M, Miura C, Kazama I (2016) Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. *Cell Physiol Biochem* 38:15–27
- Babaei S, Bayat M (2012) Effect of pentoxifylline administration on mast cell numbers and degranulation in a diabetic and normoglycemic rat model wound healing. *Iran Red Crescent Med J* 14:483–487
- Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F (2005) The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. *J Immunol* 175:7989–7995
- Bae MH, Kim HK, Park CJ, Seo EJ, Park SH, Cho YU, Jang S, Chi HS, Lee KH (2013) A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation. *Ann Lab Med* 33:125–129
- Baek OS, Kang OH, Choi YA, Choi SC, Kim TH, Nah YH, Kwon DY, Kim YK, Kim YH, Bae KH, Lim JP, Lee YM (2003) Curcumin inhibits protease-activated receptor-2 and -4-mediated mast cell activation. *Clin Chim Acta* 338:135–141
- Bairlein M (2010) Characterization of the small molecule kinase inhibitor SU11248 (sunitinib/SUTENT) in vitro and in vivo—towards response prediction in cancer therapy with kinase inhibitors. TU Munich, Munich, Germany, Medical thesis
- Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Coignard-Biehler H, Georin-Lavialle S, Lhermitte L, Fraitag S, Canioni D, Dubreuil P, Hermine O (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. *Blood* 126:1009–1016
- Bell MC, Jackson DJ (2012) Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. *Ann Allergy Asthma Immunol* 108:383–384
- Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M (2014) Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. *Haematologica* 99:417–429
- Bidri M, Royer B, Averlant G, Bismuth G, Guillosson JJ, Arock M (1999) Inhibition of mouse mast cell proliferation and proinflammatory mediator release by benzodiazepines. *Immunopharmacology* 43:75–86

- Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, Shepherd SJ, Muir JG, Gibson PR (2011) Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. *Am J Gastroenterol* 106:508–514
- Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Scherthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P (2010) In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. *Exp Hematol* 38:744–755
- Borzutzky A, Morales PS, Mezzano V, Nussbaum S, Burks W (2014) Induction of remission of frequent idiopathic anaphylaxis with rituximab. AAAAI Meeting 28.2.-04.03, abstract 91
- Boyce JA (2007) Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. *Immunol Rev* 217:168–185
- Breslow RG, Caiado J, Castells MC (2009) Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. *Ann Allergy Asthma Immunol* 102:155–160
- Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, Møller MB, Bindslev-Jensen C, Mastocytosis Centre Odense University Hospital (MastOUH) (2013) KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. *J Allergy Clin Immunol* 132:723–728
- Broyd H, Koffer A, Assem ESK (2005) Effect of cyclosporin-A on secretion from intact and permeabilised mast cells. *Inflamm Res* 54(Supplement 1):7–8
- Butterfield JH (2005) Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. *Acta Haematol* 114:26–40
- Butterfield JH (2009) Survey of aspirin administration in systemic mastocytosis. *Prostaglandins Other Lipid Mediat* 88:122–124
- Butterfield JH, Chen D (2016) Response of patients with indolent systemic mastocytosis to tamoxifen citrate. *Leuk Res* 40:10–16
- Butterfield JH, Weiler CR (2008) Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D₂ production. *Int Arch Allergy Immunol* 147:338–343
- Butterfield JH, Tefferi A, Kozuh GF (2005) Successful treatment of systemic mastocytosis with high-dose interferon- α : long-term follow-up of a case. *Leuk Res* 29:131–134
- Cardet JC, Akin C, Lee MJ (2013) Mastocytosis: update on pharmacotherapy and future directions. *Expert Opin Pharmacother* 14:2033–2045
- Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. *J Allergy Clin Immunol* 119:1550–1551
- Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphaël M, Guillemin L, Lortholary O (2002) Treatment of adult systemic mastocytosis with interferon- α : results of a multicentre phase II trial on 20 patients. *Br J Haematol* 119:1090–1097
- Caughy GH (2016) Mast cell proteases as pharmacological targets. *Eur J Pharmacol* 778:44–55
- Chan JJ, Kasprovicz S, Tharp MD (2013) Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis. *Clin Exp Dermatol* 38:538–544
- Chandesris MO, Damaj G, Canioni D, Brouzes C, Cabaret L, Hanssens K, Durieu I, Durupt S, Besnard S, Beyne-Rauzy O, Launay D, Schiffmann A, Niault M, Ranta D, Agape P, Faure C, Chantepie SP, Daguindau N, Bourgeat P, Dubreuil P, Lortholary O, Hermine O (2014) Treatment of advanced systemic mastocytosis with PKC412: the French compassionate use programme experience and historical comparison. *ASH Meeting*, abstract 3193
- Chatterjee IB, Gupta SD, Majumder AK, Nandi BK, Subramanian N (1975) Effect of ascorbic acid on histamine metabolism in scorbutic guinea-pigs. *J Physiol* 251:271–279
- Church MK, Gradidge CF (1980) Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. *Br J Pharmacol* 69:663–667
- Cikler E, Ersoy Y, Cetinel S, Ercan F (2009) The leukotriene d₄ receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. *Acta Histochem* 111:112–118
- Clemons A, Vasiadi M, Kempuraj D, Kourelis T, Vandoros G, Theoharides TC (2011) Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. *J Clin Psychopharmacol* 31:385–387
- Cohen SS, Skovbo S, Vestergaard H, Kristensen T, Møller M, Bindslev-Jensen C, Fryzek JP, Broesby-Olsen S (2014) Epidemiology of systemic mastocytosis in Denmark. *Br J Haematol* 166:521–528
- Cooper K, Young J, Wadsworth S, Cui H, diZerega GS, Rodgers KE (2007) Reduction of post-surgical adhesion formation with tranilast. *J Surg Res* 141:153–161
- Corbin AS, Griswold IJ, La Rosée P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW (2004) Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. *Blood* 104:3754–3757
- Correia O, Duarte AF, Quirino P, Azevedo R, Delgado L (2010) Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. *Dermatol Online J* 16:8
- Damaj G, Bernit E, Ghez D, Claisse JF, Schleinitz N, Harlé JR, Canioni D, Hermine O (2008) Thalidomide in advanced mastocytosis. *Br J Haematol* 141:249–253
- De Filippis D, D'Amico A, Iuvone T (2008) Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. *J Neuroendocrinol* 20(Suppl 1):20–25
- Dix S, Cord M, Howard S, Coon J, Belt R, Geller R (1999) Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. *Bone Marrow Transplant* 24:561–566
- Droogendijk HJ, Kluin-Nelemans HJC, van Doormaal JJ, Oranje AR, van de Loosdrecht AA, van Daele PLA (2006) Imatinibmesylate in the treatment of systemic mastocytosis: a phase II trial. *Cancer* 107:345–351
- Dueñas-Laita A, Ruiz-Muñoz P, Armentia A, Pinacho F, Martín-Armentia B (2009) Successful treatment of chronic drug-resistant urticaria with alprazolam. *J Allergy Clin Immunol* 123:504–505
- Duffy SM, Lawley WJ, Kaur D, Yang W, Bradding P (2003) Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. *J Allergy Clin Immunol* 112:965–972
- Edwards AM, Hagberg H (2010) Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report. *J Med Case Rep* 4:193
- Edwards AM, Stevens MT, Church MK (2011) The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial. *BMC Res Notes* 4:47
- El-Agamy DS (2012) Anti-allergic effects of nilotinib on mast cell-mediated anaphylaxis like reactions. *Eur J Pharmacol* 680:115–121
- El-Feki G, X Zhou, LC Lau, J Pedersen, AF Walls (2011) Inhibitors of dipeptidyl peptidase I (DPPI) as mast cell stabilising agents: the contribution of DPPI in mast cell activation. *J Allergy Clin Immunol* 127, Suppl. – Abstracts
- Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A (2014) The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. *Ann Hematol* 93:81–88

- Escribano L, Akin C, Castells M, Schwartz LB (2006) Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. *Inflamm Allergy Drug Targets* 5:61–77
- Eskandari N, Bastan R, Peachell PT (2015) Regulation of human skin mast cell histamine release by PDE inhibitors. *Allergol Immunopathol (Madr)* 43:37–41
- Estévez MD, Vieytes MR, Botana LM (1996) Mitoxantrone induces nonimmunological histamine release from rat mast cells. *Inflamm Res* 45:113–117
- Evans E, Gardino A, Hodous B, Davis A, Zhu J, Kohl NE, Lengauer C (2015) Blu-285, a potent and selective inhibitor for hematologic malignancies with KIT exon 17 mutations. *ASH Annual Meeting: abstract 568*
- Evora PR, Simon MR (2007) Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. *Ann Allergy Asthma Immunol* 99:306–313
- Facci L, Dal Toso R, Romanello S, Burianni A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci U S A* 92:3376–3380
- Finn DF, Walsh JJ (2013) Twenty-first century mast cell stabilisers. *Br J Pharmacol* 170:23–37
- Frenkel A, Roy-Shapira A, Evgeni B, Leonid K, Borer A, Klein M (2015) Life threatening idiopathic recurrent angioedema responding to cannabis. *Case Rep Immunol* 2015:780824
- Friedman BS, Santiago ML, Berkebile C, Metcalfe DD (1993) Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. *J Allergy Clin Immunol* 92:520–526
- Frieri M, Alling DW, Metcalfe DD (1985) Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. *Am J Med* 78:9–14
- Fujimoto T, Nishiyama T, Hanaoka K (2005) Inhibitory effects of intravenous anesthetics on mast cell function. *Anesth Analg* 101:1054–1059
- Fumo G, Akin C, Metcalfe DD, Neckers L (2004) 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. *Blood* 103:1078–1084
- Galli SJ, Costa JJ (1995) Mast-cell-leukocyte cytokine cascades in allergic inflammation. *Allergy* 50:851–862
- Gibbs BF, Schmutzler W, Vollrath IB, Brosthardt P, Braam U, Wolff HH, Zwadlo-Klarwasser G (1999) Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. *Inflamm Res* 48:86–93
- Giraldo Castellano P, García-Erce JA, Alvarez Alegret R, Arroyo Rubio A, Mayayo Artal P, Vicente Cámara P, Rubio-Félix D, Giral RM (1998) Interferon alpha and systemic mastocytosis. Analysis of therapeutic efficacy in 6 cases. *Rev Clin Esp* 198:345–350
- Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijušufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P (2011) KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk-activation and disruption by dasatinib and bosutinib. *Blood* 118:1885–1898
- Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijušufovic E, Valent P (2013) Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. *Haematologica* 98:1450–1457
- Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C, DeAngelo DJ, Kepten I, Lanza C, Heinemann H, Yin O, Gallagher N, Graubert T (2008) The KIT tyrosine kinase inhibitor midostaurin (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial. *Blood* 110:1039A
- Gotlib J, Kluijn-Neelemans HC, George TI et al. (2014) Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 trial. *Blood*;124: ASH Annual Meeting Abstracts; Abstract 636
- Gri G, Frossi B, D'Inca F, Danelli L, Betto E, Mion F, Sibilano R, Pucillo C (2012) Mast cell: an emerging partner in immune interaction. *Front Immunol* 3:120
- Gromke T, Elmaagacli AH, Ditschkowski M, Hegerfeldt Y, Koldehoff M, Hlinka M, Ottinger H, Trenschele R, Beelen DW (2013) Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation. *Bone Marrow Transplant* 48:732–733
- Gruson B, Lortholary O, Canioni D, Chandesris O, Lantermier F, Bruneau J, Grosbois B, Livideanu C, Larroche C, Durieu I, Barete S, Sevestre H, Diouf M, Chaby G, Marolleau JP, Dubreuil P, Hermine O, Damaj G (2013) Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. *Br J Haematol* 161:434–442
- Gurgel JA, Lima-Júnior RC, Rabelo CO, Pessoa BB, Brito GA, Ribeiro RA (2013) Amitriptyline, clomipramine, and maprotiline attenuate the inflammatory response by inhibiting neutrophil migration and mast cell degranulation. *Rev Bras Psiquiatr* 35:387–392
- Hadzijušufovic E, Peter B, Herrmann H, Schuch, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl W, Willmann M, Valent P (2010) Mutations in KIT predict resistance to several TKI (sorafenib, sunitinib, and masitinib) in neoplastic human and canine mast cell lines. *Haematologica* 95(suppl.2):357 abs. 0857
- Haenisch B, Nöthen MM, Molderings GJ (2012) Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. *Immunology* 137:197–205
- Haenisch B, Fröhlich H, Herms S, Molderings GJ (2014) Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. *Immunogenetics* 66:287–297
- Hagel AF, Layritz CM, Hagel WH, Hagel HJ, Hagel E, Dauth W, Kressel J, Regnet T, Rosenberg A, Neurath MF, Molderings GJ, Raithe M (2013) Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. *Naunyn Schmiedeberg's Arch Pharmacol* 386:789–793
- Hagenlocher Y, Kießling K, Schäffer M, Bischoff SC, Lorentz A (2015) Cinnamaldehyde is the main mediator of cinnamon extract in mast cell inhibition. *Eur J Nutr* 54:1297–1309
- Hamilton MJ, Homick JL, Akin C, Castells MC, Greenberger NJ (2011) Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. *J Allergy Clin Immunol* 128:147–152
- Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. *Proc Natl Acad Sci U S A* 104:13283–13288
- Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, Blank U, Nilsson G, Maurer M (2014) Molecular targets on mast cells and basophils for novel therapies. *J Allergy Clin Immunol* 134:530–544
- Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P (2004) Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. *Leuk Res* 28:249–257
- Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dimhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225 (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clin Cancer Res* 14:2717–2725

- Hennessy B, Giles F, Cortes J, O'Brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S (2004) Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. *Am J Hematol* 77:209–214
- Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barette S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A (2008) Case-control cohort study of patients' perceptions of disability in mastocytosis. *PLoS One* 3:e2266
- Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwager AP, Gratwohl A, Rafferty T, Resta D, Gattermann N (2006) A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. *Blood* 108: Abstract 2703 [ASH Annual Meeting Abstracts]
- Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, Müller MC, Reiter A, Santanastasio H, Leung M, Novick S, Kantarjian HM (2015) Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. *J Cancer Res Clin Oncol* 141:2047–2060
- Hoffmann K, Xifró RA, Hartweg JL, Spitzlei P, Meis K, Molderings GJ, von Kügelgen I (2013) Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells. *Eur J Pharmacol* 700:152–158
- Horan RF, Sheffer AL, Austen KF (1990) Cromolyn sodium in the management of systemic mastocytosis. *J Allergy Clin Immunol* 85:852–855
- Ibelgaufs H. (2016). "Mast Cells" in COPE: cytokines and cells online pathfinder encyclopaedia, Available at <http://www.cells-talk.com> (accessed March 21, 2016)
- Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan A (2008) Concurrent inhibition of KIT- and FcεRI-mediated signaling: coordinated suppression of mast cell activation. *J Pharmacol Exp Ther* 324:128–138
- Jin B, Ding K, Pan J (2014) Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing beta-catenin signaling. *Mol Cancer Ther* 13: 1217–1230
- Johnston CS, Martin LJ, Cai X (1992) Antihistamine effect of supplemental ascorbic acid and neutrophil chemotaxis. *J Am Coll Nutr* 11: 172–176
- Joks R, Durkin HG (2011) Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs. *Pharmacol Res* 64:602–609
- Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H (2007) Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. *Pediatr Blood Cancer* 48: 330–332
- Kaneko I, Suzuki K, Matsuo K, Kumagai H, Owada Y, Noguchi N, Hishinuma T, Ono M (2009) Cysteinyl leukotrienes enhance the degranulation of bone marrow-derived mast cells through the autocrine mechanism. *Tohoku J Exp Med* 217:185–191
- Karlberg M, Ekoff M, Labi V, Strasser A, Huang D, Nilsson G (2010a) Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. *Cell Death Dis* 1:e43
- Karlberg M, Ekoff M, Huang DC, Mustonen P, Harvima IT, Nilsson G (2010b) The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. *J Immunol* 185: 2555–2562
- Katoh N, Hirano S, Yasuno H (1996) Solitary mastocytoma treated with traniLAST. *J Dermatol* 23:335–339
- Kay LJ, Yeo WW, Peachell PT (2006) Prostaglandin E-2 activates EP2 receptors to inhibit human lung mast cell degranulation. *Br J Pharmacol* 147:707–713
- Kempna P, Reiter E, Arocks M, Azzi A, Zingg JM (2004) Inhibition of HMC-1 mast cell proliferation by vitamin E. *J Biol Chem* 279: 50700–50709
- Kempuraj D, Castellani ML, Petrarca C, Frydas S, Conti P, Theoharides TC, Vecchiet J (2006) Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. *Clin Exp Med* 6:150–156
- Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD (1989) A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. *J Allergy Clin Immunol* 83:866–870
- Kibsgaard L, Skjold T, Deleuran M, Vestergaard C (2014) Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. *Acta Derm Venereol* 94:363–364
- Kinney SR, Carlson L, Ser-Dolansky J, Thompson C, Shah S, Gambah A, Xing W, Schneider SS, Mathias CB (2015) Curcumin ingestion inhibits mastocytosis and suppresses intestinal anaphylaxis in a murine model of food allergy. *PLoS One* 10:e0132467
- Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R (2003) Cladribine therapy for systemic mastocytosis. *Blood* 102:4270–4276
- Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, van Iperen C, Peters WG, Akin C, Valent P (2009) Lenalidomide therapy in systemic mastocytosis. *Leuk Res* 33:e19–e22
- Knapper S, Cullis J, Drummond MW, Evelyn R, Everington T, Hoyle C, McLintock L, Poynton C, Radia D (2011) Midostaurin a multi-targeted oral kinase inhibitor in systemic mastocytosis: report of an open-label compassionate use program in the United Kingdom. *Blood* 118:5145
- Koelink PJ, Overbeek SA, Braber S, de Kruijff P, Folkerts G, Smit MJ, Kraneveld AD (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. *Pharmacol Ther* 133: 1–18
- Kohno M, Yamasaki S, Tybulewicz VLJ, Saito T (2005) Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen. *Blood* 105:2059–2065
- Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG (2010) Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. *Ann Allergy Asthma Immunol* 104:537–539
- Krauth MT, Majlesi Y, Sonneck K, Samorapoompichit P, Ghannadan M, Hauswirth AW, Baghestanian M, Schernthaner GH, Worda C, Muller MR, Sperr WR, Valent P (2006) Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. *Allergy* 61:281–288
- Krauth MT, Böhm A, Agis H, Sonneck K, Samorapoompichit P, Florian S, Sotlar K, Valent P (2007) Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. *Exp Hematol* 35:108–116
- Krug U, Lübbert M, Büchner T (2010) Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? *Curr Opin Hematol* 17:85–90
- Kurosawa M, Amano H, Kanbe N, Igarashi Y, Nagata H, Yamashita T, Kurimoto F, Miyachi Y (1999) Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. *J Allergy Clin Immunol* 103:S412–S420
- Kurzen H. (2009) Neramexane for the treatment of mast cell-mediated diseases. Patent application WO2010/069595
- Kvasnicka HM, Thiele J, Bueso-Ramos CE, Kamalanabhaiah S, Cortes JE, Kantarjian H, Verstovsek S (2014) Changes in activated bone marrow macrophages and mast cells in patients with myelofibrosis following ruxolitinib therapy. *ASH Meeting abstract* 3184

- Laengle UW, Markstein R, Pralet D, Seewald W, Roman D (2006) Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. *Exp Eye Res* 83:1335–1339
- Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. *Am J Med* 124:776–778
- Lasho T, Tefferi A, Pardanani A (2010) Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. *Leukemia* 24:1378–1380
- Lasho T, Finke C, Zblewski D et al. (2016) Concurrent activating KIT mutations in systemic mastocytosis. *Br J Haematol* 173:153–156
- Lau HY, Kam MF (2005) Inhibition of mast cell histamine release by specific phosphodiesterase inhibitors. *Inflamm Res* 54(Supplement 1):05–06
- Lechowski S, Feilhauer K, Staib L, Coëffier M, Bischoff SC, Lorentz A (2013) Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells. *Eur J Nutr* 52:505–512
- Lee YS, Kim MS, Lee DH, Kwon TH, Song HH, Oh SR, do Yoon Y (2015) Luteolin 8-C- β -fucopyranoside downregulates IL-6 expression by inhibiting MAPKs and the NF- κ B signaling pathway in human monocytic cells. *Pharmacol Rep* 67:581–587
- Lieberoth S, Thomsen SF (2015) Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. *Case Rep Med* 2015:903541
- Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A (2009) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. *Am J Hematol* 84:790–794
- Lin TY, Bear M, Du Z, Foley KP, Ying W, Barsoum J, London C (2008) The novel HSP90 inhibitor STA-9090 exhibits activity against KIT-dependent and -independent malignant mast cell tumors. *Exp Hematol* 36:1266–1277
- Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA (2010) AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated KIT. *Blood* 115:4217–4225
- Lock AD, McNamara CJ, Rustin MH (2015) Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine. *Clin Exp Dermatol* 40:142–145
- Lundequist A, Pejler G (2011) Biological implications of preformed mast cell mediators. *Cell Mol Life Sci* 68:965–975
- Ma Z, Tovar JP, Kwong KY, Paek D (2010) Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. *Int Arch Allergy Immunol* 153:413–418
- Mallet AI, Norris P, Rendell NB, Wong E, Greaves MW (1989) The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis. *Br J Clin Pharmacol* 27:88–91
- Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G (2014) Masitinib (AB1010), from canine tumor model to human clinical development: where we are? *Crit Rev Oncol Hematol* 91:98–111
- Marquardt DL, Gruber HE, Walker LL (1987) Ribavirin inhibits mast cell mediator release. *J Pharmacol Exp Ther* 240:145–149
- Marton I, Pósfai É, Borbényi Z, Bődör C, Papp G, Demeter J, Korom I, Varga E, Bata-Csörgő Z (2015) Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement. *Eur Rev Med Pharmacol Sci* 19:1607–1609
- Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, Miyahara N, Miyahara S, Lucas JJ, Dakhama A, Gelfand EW (2006) Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. *Am J Respir Crit Care Med* 173:56–63
- Mattace Raso G, Russo R, Calignano A, Meli R (2014) Palmitoylethanolamide in CNS health and disease. *Pharmacol Res* 86:32–41
- Maurer M, Magerl M, Metz M, Weller K, Siebenhaar F (2013) Miltefosine: a novel treatment option for mast cell-mediated diseases. *J Dermatolog Treat* 24:244–249
- McNeil BD, Pundir P, Meeker S, Han L, Udem BJ, Kulka M, Dong X (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* 519:237–241
- Meeran SM, Ahmed A, Tollefsbol TO (2010) Epigenetic targets of bioactive dietary components for cancer prevention and therapy. *Clin Epigenetics* 1:101–116
- Min YD, Choi CH, Bark H, Son HY, Park HH, Lee S, Park JW, Park EK, Shin HI, Kim SH (2007) Quercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell line. *Inflamm Res* 56:210–215
- Molderings GJ (2015) The genetic basis of mast cell activation disease—looking through a glass darkly. *Crit Rev Oncol Hematol* 93:75–89
- Molderings GJ (2016) Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features. *Transl Res*
- Molderings GJ, Kolck UW, Scheurlen C, Brüß M, Homann J, Von Kügelgen I (2007) Multiple novel alterations in KIT tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. *Scand J Gastroenterol* 42:1045–1053
- Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T (2010) Comparative analysis of mutation of tyrosine kinase KIT in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. *Immunogenetics* 62:721–727
- Molderings GJ, Brettner S, Homann J, Afrin LB (2011a) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. *J Hematol Oncol* 4:10
- Molderings GJ, Raithe M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J (2011b) Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. *Intern Med* 50:1–5
- Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM (2013a) Familial occurrence of systemic mast cell activation disease. *PLoS One* 8:e76241
- Molderings GJ, Haenisch B, Homann J, Wilhelm T, Huber M (2013b) Neue Angriffspunkte der 1-4-Benzodiazepine in der mastzellspezifischen immunsuppressiven Therapie der systemischen Mastzellüberaktivitätserkrankung. *Gastroenterologie* 8:170 abstract
- Molderings GJ, Homann J, Brettner S, Raithe M, Frieling T (2014) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. *Dtsch Med Wochenschr* 139:1523–1534
- Moon PD, Lee BH, Jeong HJ, An HJ, Park SJ, Kim HR, Ko SG, Um JY, Hong SH, Kim HM (2007) Use of scopoletin to inhibit the production of inflammatory cytokines through inhibition of the I κ B/NF- κ B signal cascade in the human mast cell line HMC-1. *Eur J Pharmacol* 555:218–225
- Mousli M, Hugli TE, Landry Y, Bronner C (1994) Peptidergic pathway in human skin and rat peritoneal mast cell activation. *Immunopharmacology* 27:1–11
- Moussy A, Kinet JP (2014) Treatment of mastocytosis with masitinib. *US Patent Application*
- Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. *Cancer Res* 69:6941–6950

- Nader MA (2011) Inhibition of anaphylaxis like reaction and mast cell activation by sitagliptin. *Int Immunopharmacol* 11:1052–1056
- Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ (2006) A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. *Bone Marrow Transplant* 37:353–358
- Nolte H, Stahl Skov P (1988) Inhibition of basophil histamine release by methotrexate. *Agents Actions* 23:173–176
- Nurmatov UB, Rhatigan E, Simons FE, Sheikh A (2015) H1-antihistamines for primary mast cell activation syndromes: a systematic review. *Allergy* 70:1052–1061
- Oppong E, Flink N, Cato AC (2013) Molecular mechanisms of glucocorticoid action in mast cells. *Mol Cell Endocrinol* 380:119–126
- Otani IM, Bhagat M, Newbury RO, Dohil R, Broide DH, Aceves SS (2012) The effect of anti-IL-5 therapy on esophageal mastocytosis in pediatric eosinophilic esophagitis. *J Allergy Clin Immunol* 129:AB202
- Paez P, Ryan J, Taruselli M, Ndaw V (2015) Fluvastatin elicits apoptosis in primary and transformed mast cells (INC6P.305). *J Immunol* 194(Suppl. 1):197.7
- Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P (2008) Advanced mast cell disease: an Italian Hematological Multicenter experience. *Int J Hematol* 88:483–488
- Paivandy A, Calounova G, Zamegar B, Ohrvik H, Melo FR, Pejler G (2014) Mefloquine, an anti-malaria agent, causes reactive oxygen species-dependent cell death in mast cells via a secretory granule-mediated pathway. *Pharmacol Res Perspect* 2:e00066
- Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S (2007) EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. *Blood* 109:315–322
- Papaetis GS, Syrigos KN (2009) Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. *BioDrugs* 23:377–389
- Papayannidis C, Soverini S, Benedittis CD, Abbenante MC, Sartor C, Iacobucci I, Baldazzi C, Ottaviani E, Ferrari A, Guadagnuolo V, Conficoni A, Paolini S, Parisi S, Frabetti F, Piccarì S, Grilli S, Lani E, Martinelli G (2014) PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis patients: follow up of a single-center Italian compassionate use. *Cancer Res* 74:746
- Pardanani A (2013) Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. *Am J Hematol* 88:612–624
- Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A (2003) Imatinib for systemic mast-cell disease. *Lancet* 362:535–536
- Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. *Leuk Res* 28:127–131
- Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S (2010) Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. *Leuk Lymphoma* 51:269–274
- Park TH (2013) The effects of botulinum toxin A on mast cell activity: preliminary results. *Burns* 39:816–817
- Paul C, Sans B, Suarez F, Casassus P, Barete S, Lantermier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O (2010) Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. *Am J Hematol* 85:921–925
- Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P (2010) KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). *Exp Hematol* 38:782–791
- Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Mullauer L, Willmann M, Valent P (2011) Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536. *Haematologica* 96(5):672–680
- Picard M, Giavina-Bianchi P, Mezzano V, Castells M (2013) Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. *Clin Ther* 35:548–562
- Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B, Cannell P (2008) Dasatinib therapy for systemic mastocytosis: four cases. *Eur J Haematol* 80:456–458
- Quintas-Cardama A, Jain N, Verstovsek S (2011) Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. *Cancer* 117:5439–5449
- Quintas-Cardama A, Sever M, Cortes J, Kantarjian H, Verstovsek S (2013) Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. *Leuk Lymphoma* 54:1959–1964
- Radojković M, Ristić S, Colović N, Terzić T, Colović M (2011) Response to cladribine in patient with systemic mastocytosis. *Vojnosanit Pregl* 68:444–446
- Randall N, Courville EL, Baughn L, Afrin L, Ustun C (2015) Bosutinib, a lyn/btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis. *Am J Hematol* 90:E74
- Ritter M, El-Nour H, Hedblad MA, Butterfield JH, Beck O, Stephanson N, Holst M, Giscombe R, Azmitia EC, Nordlind K (2012) Serotonin and its 5-HT1 receptor in human mastocytosis. *Immunopharmacol Immunotoxicol* 34:679–685
- Rodrigo L, Perez-Martinez I, Lucendo AJ (2013) Urticaria pigmentosa in a female patient with celiac disease: response to a gluten-free diet. *Allergol Immunopathol (Madr)* 41:128–130
- Rodrigues JM, Pazin Filho A, Rodrigues AJ, Vicente WV, Evora PR (2007) Methylene blue for clinical anaphylaxis treatment: a case report. *Sao Paulo Med J* 125:60–62
- Rodriguez T, Pfeffer M, Levy BD, Castells M (2011) Lipid mediators in cutaneous and systemic mastocytosis and the impact of 5-LO inhibition. *J Allergy Clin Immunol* 127(Suppl):AB132
- Rosen H, Goetzl EJ (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. *Nat Rev Immunol* 5:560–570
- Ruano I, Gargini R, Izquierdo M (2010) Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. *Br J Haematol* 148:59–68
- Sagi L, Solomon M, Baum S, Lyakhovitsky A, Trau H, Barzilai A (2011) Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. *Acta Derm Venereol* 91:303–306
- Sandler C, Nurmi K, Lindstedt KA, Sorsa T, Golub LM, Kovanen PT, Eklund KK (2005) Chemically modified tetracyclines induce apoptosis in cultured mast cells. *Int Immunopharmacol* 5:1611–1621
- Schittenhelm MM, Akmut F, Illing B, Frey J, Schuster K, Ramachandran A, Kanz L, Kampa-Schittenhelm KM (2014) Gain-of-function KIT mutations sensitize the mutant isoform to the type I tyrosine kinase inhibitor crenolanib: a rationale for the therapeutic use in systemic mastocytosis (SM) and core binding factor leukemias (CBFL). *ASH-Meeting abstract* 2230
- Seifert R (2015) How do basic secretagogues activate mast cells? *Naunyn Schmiedeberg's Arch Pharmacol* 388:279–281
- Shimoda T, Liang Z, Suzuki H, Kawana S (2010) Inhibitory effects of antipsychotic and anxiolytic agents on stress-induced degranulation of mouse dermal mast cells. *Clin Exp Dermatol* 35:531–536
- Sido B, Dumoulin FL, Homann J, Hertfelder HJ, Bollmann M, Molderings GJ (2014) Surgical interventions in patients with mast

- cell activation disease. Aspects relevant for surgery using the example of a cholecystectomy. *Chirurg* 85:327–333
- Siebenhaar F, Förtsch A, Krause K, Weller K, Metz M, Magerl M, Martus P, Church MK, Maurer M (2013) Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. *Allergy* 68:949–952
- Simhadri VR, Andersen JF, Calvo E, Choi SC, Coligan JE, Borrego F (2012) Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. *Blood* 119:2799–2809
- Simon J, Lortholary O, Caillat-Vigneron N, Raphael M, Martin A, Briere J, Barete S, Hermine O, Casussus P (2004) Interest of interferon alpha in systemic mastocytosis. The french experience and review of the literature. *Pathol Biol* 52:294–299
- Soter NA, Austen KF, Wasserman SI, Soter NA, Austen KF, Wasserman SI (1979) Oral disodium cromoglycate in the treatment of systemic mastocytosis. *N Engl J Med* 301:465–469
- Spirkoski J, Melo FR, Grujic M, Calounova G, Lundequist A, Wernersson S, Pejler G (2012) Mast cell apoptosis induced by siramesine, a sigma-2 receptor agonist. *Biochem Pharmacol* 84:1671–1680
- Spyridonidis A, Thomas AK, Bertz H, Zeiser R, Schmitt-Graff A, Lindemann A, Waller CF, Finke J (2004) Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 34:515–519
- Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J (2015) Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol* 90:276–281
- Suzuki-Nishimura T, Sano T, Uchida MK (1989) Effects of benzodiazepines on serotonin release from rat mast cells. *Eur J Pharmacol* 167:75–85
- Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T, Blumberg RS, Nakajima A (2008) Activation of peroxisome proliferator-activated receptor gamma suppresses mast cell maturation involved in allergic diseases. *Allergy* 63:1136–1147
- Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H (2005) A novel NF-kappa B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-Kit receptors. *Blood* 105:2324–2331
- Tang C, Lan C, Wang C, Liu R (2005) Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells. *Shock* 23:470–475
- Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M (2015) Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. *Inflamm Res* 64:41–51
- Tefferi A, Li CY, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast-cell disease with cladribine. *N Engl J Med* 344:307–309
- Tolar J, Tope WD, Neglia JP (2004) Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. *N Engl J Med* 350:735–736
- Topar G, Staudacher C, Geisen F, Gabl C, Fend F, Herold M, Greil R, Fritsch P, Sepp N (1998) Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. *Am J Clin Pathol* 109:279–285
- Trojan TD, Khan DA (2012) Calcineurin inhibitors in chronic urticaria. *Curr Opin Allergy Clin Immunol* 12:412–420
- Tumer PJ, Kemp AS, Rogers M, Mehr S (2012) Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. *Pediatr Dermatol* 29:222–223
- Uchida K, Mitsui M, Kawakishi S (1989) Monooxygenation of N-acetylhistamine mediated by L-ascorbate. *Biochim Biophys Acta* 991:377–379
- Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P (2014) Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. *J Clin Oncol* 32:3264–3274
- Vaali K, Lappalainen J, Lin AH, Mäyränpää MI, Kovanen PT, Berstad A, Eklund KK (2012) Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy. *Neurogastroenterol Motil* 24:e325–e335
- Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res* 25:603–625
- Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluijn-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. *Eur J Clin Invest* 37:435–453
- Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. *Blood* 116:5812–5817
- Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P, Nedoszytko B, Orfao A, Schwartz LB, Sotlar K, Sperr WR, Triggiani M, Valenta R, Horny HP, Metcalfe DD (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. *Int Arch Allergy Immunol* 157:215–225
- van Doormaal JJ, Idema IG, de Monchy JG, Breukelman H, Keyzer JJ, Doorenbos H (1986) Effects of isoprenaline and terbutaline on urinary excretion of histamine and its two main metabolites in systemic mastocytosis. *Agents Actions* 18:269–272
- van Doormaal JJ, Arends S, Brunekreef KL, et al. (2013) Prevalence of indolent systemic mastocytosis in a Dutch region. *J Allergy Clin Immunol* 131:1429–1431
- Vega-Ruiz A, Cortes JE, Sever M, Manshoury T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S (2009) Phase II study of imatinibmesylate as therapy for patients with systemic mastocytosis. *Leuk Res* 33:1481–1484
- Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshoury T, Thomas D, Kantarjian H (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clin Cancer Res* 14:3906–3915
- Vrugt B, Wilson S, Bron A, Shute J, Holgate ST, Djukanovic R, Aalbers R (2000) Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogen-induced T-cell proliferation. *Eur Respir J* 15:478–485
- Welch EA, Alper JC, Bogaars H, Farrell DS (1983) Treatment of bullous mastocytosis with disodium cromoglycate. *J Am Acad Dermatol* 9:349–353
- Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, Dos Santos RV, Sünder C, Zuberbier T, Maurer M (2009) Miltefosine inhibits

- human mast cell activation and mediator release both in vitro and in vivo. *J Invest Dermatol* 129:496–498
- Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. *PLoS One* 7:e33805
- Weng Z, Patel AB, Panagiotidou S, Theoharides TC (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. *J Allergy Clin Immunol* 135:1044–1052
- Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD (1996) Treatment of three patients with systemic mastocytosis with interferon alpha-2b. *Leuk Lymphoma* 22:501–508
- Yacoub A, Prochaska L (2016) Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. *Biomark Res* 4:2
- Yamaguchi S, Okada Y, Matsunaga Y, Nambu F (2016) Effect of ONO-4053 on FcεRI stimulated mast cell activation. *J Allergy Clin Immunol* 137:AB77
- Yamaki K, Yoshino S (2012) Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice. *Allergy* 67:114–122
- Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, Reagan JD (2010) G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. *Pharmacology* 86:1–5
- Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y (2009) Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. *Intern Med* 48:1973–1978
- Zachariae H, Herlin T, Larsen PO (1981) Oral disodium cromoglycate in mastocytosis. *Acta Derm Venereol* 61:272–273
- Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A (2011) The kaleidoscope of glucocorticoid effects on immune system. *Autoimmun Rev* 10:305–310
- Zhang T, Finn DF, Barlow JW, Walsh JJ (2016) Mast cell stabilisers. *Eur J Pharmacol* 778:158–168